Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LGND vs XOMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Captures Overall Composite Edge (55.8 HOLD vs 42.6 HOLD), While LGND Leads 4–2 on Growth & Valuation Pillars

XOMA Overall Winner 6-Pillar Tally: LGND 4 – 2 XOMA Matrix Metrics: LGND 3 – 7 XOMA

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) captures the overall head-to-head institutional edge over Ligand Pharmaceuticals Inc. (LGND) on higher Unified Composite conviction (55.8/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while LGND wins 4–2 across the 6-pillar growth and valuation breakdown. LGND trades at $301.87 (25.8x Forward P/E, 14.4% operating margin) versus XOMA at $40.17 (21.5x Forward P/E, -3.9% operating margin).

  • Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. LGND 42.6/100 HOLD) and 0.68β · 37% Vol risk profile, whereas LGND leads top-line expansion (-31.8% YoY revenue growth, 1.53x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LGND vs XOMA
LGND NASDAQ
Ligand Pharmaceuticals Inc.
Pharmaceutical Preparations
$301.87
-2.24% 1D
Market Cap $6.3B
TTM Revenue $254M
Forward P/E 25.8x
Beta / 30D Vol 0.99β · 38% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 44.0 Fund 47.0 Flow 63.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.6 · SMA20: $311.42 · SMA50: $302.10
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06

6-Pillar Scorecard Institutional Category Breakdown (LGND 4 – 2 XOMA)

Columns: Metric · LGND · XOMA
1. Valuation Multiples XOMA
Forward P/E 25.8x 21.5x
Trailing P/E 127.0x 28.2x
PEG Ratio 1.53x N/M
EV / Revenue 29.3x 16.1x
2. Growth & Scale LGND
Revenue Growth (YoY) -31.8% -22.6%
Earnings Growth (YoY) +825.0% +207.9%
TTM Revenue (USD) $254M $49M
Market Cap $6.3B $781.8M
3. Profitability & Quality XOMA
Gross Margin 86.1% 99.0%
Operating Margin 14.4% -3.9%
Net Profit Margin 20.3% 69.6%
Return on Equity (ROE) 5.4% 34.2%
4. Balance Sheet & Cash Flow LGND
Cash Generation (TTM) $57M $8.3M EBITDA
Cash Flow Margin 22.6% 17.1% EBITDA Mgn
Net Cash / Leverage $1.10B Net Debt (1.20x D/E) $7.79 Book/Sh · 34.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LGND
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 37.9% (8th %ile) 101.5% (100th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat LGND
OpEx & R&D Intensity 71.7% of Rev ($182M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LGND (3) vs XOMA (7)
Institutional Metric LGND XOMA Criterion Row Edge
Market Capitalization
Scale
$6.3B $781.8M Larger Scale LGND
Trailing P/E Ratio
Valuation
127.0x 28.2x Lower Multiple XOMA
Forward P/E Ratio
Valuation
25.8x 21.5x Lower Multiple XOMA
Revenue Growth (YoY)
Growth
-31.8% -22.6% Higher Growth XOMA
Operating Margin (TTM)
Profitability
14.4% -3.9% Higher Margin LGND
Net Profit Margin
Profitability
20.3% 69.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
5.4% 34.2% Higher ROE XOMA
52-Week Range Position
Momentum
84% ($176–$327) 78% ($22–$45) Stronger Trend LGND
Beta / 30D Volatility
Risk Regime
0.99β · 38% Vol 0.68β · 37% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$254M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.1% 99.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.53x PEG · 29.3x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$57M ($1.10B Net Debt (1.20x D/E)) $8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LGND +28.39 pp
LGND: +24.58% · XOMA: -3.81%
3M Horizon LGND +41.57 pp
LGND: +50.91% · XOMA: +9.34%
6M Horizon LGND +20.31 pp
LGND: +54.57% · XOMA: +34.26%
1Y Horizon LGND +29.05 pp
LGND: +53.65% · XOMA: +24.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LGND vs XOMA. Trailing 12-month operating profitability (LGND 14.4% vs XOMA -3.9%) and valuation multiples (LGND 25.8x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

LGND ADR TTM Benchmark FX-Normalized USD
TTM Revenue$254M
Gross Margin86.1%
Op. Margin14.4%
ROE / Fwd P/E5.4% · 25.8x
XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LGND CONSOLIDATION
98d in phase · OBV NEUTRAL
Current IV 37.9%
IV Percentile 8th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LGND Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LGND Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and 14.4% operating margin.
OpEx & R&D Reinvestment 71.7% of Rev ($182M)
90D Engineering Disclosures 0 Published
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LGND vs XOMA Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) captures the overall head-to-head institutional edge over Ligand Pharmaceuticals Inc. (LGND) on higher Unified Composite conviction (55.8/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while LGND wins 4–2 across the 6-pillar growth and valuation breakdown. LGND trades at $301.87 (25.8x Forward P/E, 14.4% operating margin) versus XOMA at $40.17 (21.5x Forward P/E, -3.9% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. LGND 42.6/100 HOLD) and 0.68β · 37% Vol risk profile, whereas LGND leads top-line expansion (-31.8% YoY revenue growth, 1.53x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

LGND leads the Growth & Scale pillar: LGND posts -31.8% YoY revenue growth and +825.0% YoY earnings growth on $254M TTM revenue (86.1% gross margin, 14.4% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, LGND generates $254M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, LGND deploys 71.7% of Rev ($182M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.

XOMA screens cheaper on headline valuation multiples. LGND trades at 25.8x Forward P/E, 127.0x Trailing P/E, 1.53x PEG, and 29.3x EV/Revenue (22.6% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LGND (5.4% ROE) versus XOMA (34.2% ROE) capital efficiency.

In options market volatility and institutional positioning, LGND carries 37.9% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.99β · 38% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.